Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Patritumab |
| Trade Name | |
| Synonyms | U3-1287|AMG-888 |
| Drug Descriptions |
Patritumab (U3-1287) is a monoclonal antibody that targets HER3 and inhibits ligand binding, potentially resulting in decreased activation of downstream signaling and reduced tumor growth (PMID: 24442032, PMID: 31648099). |
| DrugClasses | HER3 (ERBB3) Antibody 28 |
| CAS Registry Number | 1262787-83-6 |
| NCIT ID | C78853 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Cetuximab + Patritumab | Carboplatin Cetuximab Patritumab | 0 | 0 |
| Cetuximab + Cisplatin + Patritumab | Cetuximab Cisplatin Patritumab | 0 | 0 |
| Erlotinib + Patritumab | Erlotinib Patritumab | 0 | 1 |
| Lapatinib + Patritumab | Lapatinib Patritumab | 0 | 0 |
| Patritumab | Patritumab | 0 | 0 |